Pamufetinib (mesylate)

Pamufetinib (TAS-115) mesylate is a potent VEGFRand hepatocyte growth factor receptor (c-Met/HGFR) -targeted kinase inhibitor, with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.

Product Specifications

CAS Number

[1688673-09-7]

Product Name Alternative

TAS-115 (mesylate)

UNSPSC

12352005

Target

C-Met/HGFR; VEGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/TAS-115_mesylate.html

Concentration

10mM

Purity

99.17

Solubility

DMSO : 75 mg/mL (ultrasonic)

Smiles

CS(=O)(O)=O.O=C(C1=C(OC)C=C2N=CC=C(OC3=CC=C(NC(NC(CC4=CC=CC=C4)=O)=S)C=C3F)C2=C1)NC

Molecular Formula

C28H27FN4O7S2

Molecular Weight

614.66

References & Citations

[1]Fujita H, et al. The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile. Mol Cancer Ther. 2013 Dec;12 (12) :2685-96.|[2]Nakade J, et al. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation. J Thorac Oncol. 2014 Jun;9 (6) :775-83.